

# Giovanni D Di Minno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9209299/publications.pdf>

Version: 2024-02-01

212  
papers

7,574  
citations

43973

48  
h-index

69108

77  
g-index

217  
all docs

217  
docs citations

217  
times ranked

8257  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 100-108.	1.5	21
2	Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 124-126.	1.5	5
3	Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement. <i>Blood Reviews</i> , 2022, 51, 100885.	2.8	7
4	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. <i>Haemophilia</i> , 2022, 28, 55-64.	1.0	7
5	The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. <i>Blood Reviews</i> , 2021, 46, 100737.	2.8	7
6	Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. <i>Haemophilia</i> , 2021, 27, e422-e433.	1.0	14
7	Perspective “The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. <i>Blood Reviews</i> , 2021, 50, 100849.	2.8	4
8	Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2021, 19, 542-555.	0.8	11
9	Pain assessment and management in Italian Haemophilia Centres. <i>Blood Transfusion</i> , 2021, 19, 335-342.	0.3	8
10	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4925.	1.0	27
11	RASopathies and hemostatic abnormalities: key role of platelet dysfunction. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 499.	1.2	5
12	Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	0.3	2
13	Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine. <i>Blood Reviews</i> , 2020, 39, 100618.	2.8	24
14	From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. <i>Blood Reviews</i> , 2020, 39, 100613.	2.8	16
15	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. <i>Genes</i> , 2020, 11, 1243.	1.0	5
16	International recommendations on the diagnosis and treatment of acquired hemophilia A. <i>Haematologica</i> , 2020, 105, 1791-1801.	1.7	182
17	Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. <i>Blood Transfusion</i> , 2020, 18, 152-158.	0.3	8
18	Convalescent plasma for administration of passive antibodies against viral agents. <i>Haematologica</i> , 2020, 105, 2710-2715.	1.7	3

#	ARTICLE	IF	CITATIONS
19	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020, 111, 370-372.	0.3	0
20	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and Siset. <i>Blood Transfusion</i> , 2020, 18, 143-151.	0.3	22
21	Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. <i>Blood Reviews</i> , 2019, 33, 106-116.	2.8	12
22	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 468-477.	1.5	19
23	Red Wine Consumption and Cardiovascular Health. <i>Molecules</i> , 2019, 24, 3626.	1.7	131
24	The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. <i>TH Open</i> , 2019, 03, e286-e294.	0.7	12
25	Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project. <i>Haemophilia</i> , 2019, 25, 656-667.	1.0	16
26	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. <i>Internal and Emergency Medicine</i> , 2019, 14, 447-449.	1.0	5
27	&lt;p&gt;Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A&lt;p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 233-240.	0.8	11
28	<b>Commentary on</b>: Borrini M, Carlaschelli L. A <sc>BPA</sc> Approach to the Shroud of Turin. <i>J Forensic Sci</i> 2019;64(1):137â€“43. <i>Journal of Forensic Sciences</i> , 2019, 64, 325-326.	0.9	2
29	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 37-43.	1.4	17
30	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2019, 14, 21-38.	1.0	13
31	Cytomegalovirus-Associated Splanchnic Vein Thrombosis in Immunocompetent Patients: Two Case Reports and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 298-303.	1.5	3
32	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 551-560.	1.5	12
33	Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. <i>International Journal of Cardiology</i> , 2018, 271, 366-370.	0.8	17
34	Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2350.	1.8	47
35	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. <i>Annals of Medicine</i> , 2017, 49, 329-342.	1.5	6
36	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	1.0	44

#	ARTICLE	IF	CITATIONS
37	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	1.9	108
38	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. <i>American Journal of Hematology</i> , 2017, 92, 646-652.	2.0	10
39	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 425-435.	1.0	6
40	Glanzmann's thrombasthenia: strategies for identification and management. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 641-653.	0.5	6
41	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. <i>Annals of Hematology</i> , 2017, 96, 1253-1270.	0.8	18
42	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.	0.6	19
43	Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. <i>Haematologica</i> , 2017, 102, 411-418.	1.7	14
44	Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 069-074.	1.5	12
45	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	1.0	23
46	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	1.1	12
47	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	0.9	29
48	New Insights Into the Treatment of Glanzmann Thrombasthenia. <i>Transfusion Medicine Reviews</i> , 2016, 30, 92-99.	0.9	95
49	Blood stains of the Turin Shroud 2015: beyond personal hopes and limitations of techniques. <i>Internal and Emergency Medicine</i> , 2016, 11, 507-516.	1.0	4
50	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. <i>Blood Reviews</i> , 2016, 30, 35-48.	2.8	34
51	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. <i>Blood Transfusion</i> , 2016, 14, 255-61.	0.3	21
52	The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. <i>Haematologica</i> , 2015, 100, 1038-44.	1.7	53
53	Novel oral anticoagulants in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 512-519.	0.6	10
54	Acquired Hemophilia A successfully treated with rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015024.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Prophylaxis of venous thromboembolism in elderly patients with multi-morbidity: the REPOSI data. <i>Internal and Emergency Medicine</i> , 2015, 10, 251-252.	1.0	0
56	Methylation Reactions, the Redox Balance and Atherothrombosis: The Search for a Link with Hydrogen Sulfide. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 423-432.	1.5	7
57	Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders. <i>Blood Reviews</i> , 2015, 29, S26-S33.	2.8	10
58	Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 382-388.	1.5	54
59	Laboratory tests during direct oral anticoagulant treatment? Authors'™ reply. <i>Internal and Emergency Medicine</i> , 2015, 10, 533-534.	1.0	1
60	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. <i>Blood Reviews</i> , 2015, 29, 335-343.	2.8	24
61	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. <i>Thrombosis Research</i> , 2015, 135, 923-932.	0.8	78
62	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 113-132.	1.5	7
63	The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. <i>Haematologica</i> , 2015, 100, 1031-7.	1.7	43
64	Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. <i>Thrombosis Research</i> , 2015, 136, 1074-1081.	0.8	25
65	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. <i>Journal of Clinical Investigation</i> , 2015, 125, 3766-3781.	3.9	39
66	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. <i>Blood Transfusion</i> , 2015, 13, 498-513.	0.3	48
67	Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. <i>Blood Transfusion</i> , 2015, 13, 328-32.	0.3	3
68	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014, 9, 559-67.	1.0	27
69	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. <i>Annals of Medicine</i> , 2014, 46, 475-489.	1.5	15
70	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2478-2485.	1.1	48
71	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <sc>AICE</sc> survey. <i>Haemophilia</i> , 2014, 20, e128-35.	1.0	15
72	Anticoagulant Therapy in Oncologic Patients Undergoing Venous Stenting for Superior Vena Cava Syndrome and Other Interventional Procedures. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1401-1402.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Ensuring medication adherence with direct oral anticoagulant drugs. <i>Thrombosis Research</i> , 2014, 133, 699-704.	0.8	39
74	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. <i>Thrombosis Research</i> , 2014, 134, 264-267.	0.8	12
75	Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. <i>Thrombosis and Haemostasis</i> , 2014, 112, 424-425.	1.8	13
76	HELLP syndrome and its relation with the antiphospholipid syndrome. <i>Blood Transfusion</i> , 2014, 12, 114-8.	0.3	14
77	Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s337-42.	0.3	12
78	Current and evolving features in the clinical management of haemophilia. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s554-62.	0.3	4
79	Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s582-8.	0.3	2
80	Laboratory tests during direct oral anticoagulant treatment? No. <i>Internal and Emergency Medicine</i> , 2013, 8, 367-370.	1.0	14
81	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15812-15817.	3.3	52
82	Human genome, environment and medical practice. <i>Internal and Emergency Medicine</i> , 2013, 8, 645-649.	1.0	3
83	Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 141-147.	1.5	144
84	Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?. <i>Haemophilia</i> , 2013, 19, 18-23.	1.0	15
85	Improving the use of direct oral anticoagulants in atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 288-294.	1.0	11
86	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 779-793.	1.5	12
87	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 973-973.	1.5	1
88	Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 723-731.	1.5	53
89	Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C (and Congenital) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.5	5
90	Prenatal diagnosis of haemophilia: our experience of 44 cases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2233-2238.	1.4	8

#	ARTICLE	IF	CITATIONS
91	Magnetic resonance imaging and ultrasound evaluation of "healthy" joints in young subjects with severe haemophilia A. <i>Haemophilia</i> , 2013, 19, e167-73.	1.0	60
92	Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). <i>Thrombosis and Haemostasis</i> , 2013, 109, 1170-1179.	1.8	188
93	Replacement therapy for bleeding episodes in factor VII deficiency. <i>Thrombosis and Haemostasis</i> , 2013, 109, 238-247.	1.8	48
94	Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. <i>Haematologica</i> , 2013, 98, 1495-1498.	1.7	20
95	Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). <i>Haematologica</i> , 2013, 98, 538-544.	1.7	82
96	The role of the metabolic syndrome in patients with provoked venous thromboembolic events. <i>Thrombosis and Haemostasis</i> , 2013, 109, 759-761.	1.8	6
97	Clinical use of factor VIII and factor IX concentrates. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s55-63.	0.3	16
98	Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s101-9.	0.3	5
99	Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor- $\alpha$ Blockers. <i>Journal of Rheumatology</i> , 2012, 39, 1042-1046.	1.0	38
100	Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 497-505.	1.5	46
101	The Infectious Burden in Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 515-523.	1.5	39
102	Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor- $\alpha$ Blockers. <i>Journal of Rheumatology</i> , 2012, 39, 568-573.	1.0	48
103	Filling the gap between science & clinical practice: Prevention of stroke recurrence. <i>Thrombosis Research</i> , 2012, 129, 3-8.	0.8	14
104	Platelet Reactivity and Disease Activity in Subjects with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 334-336.	1.0	32
105	Urinary excretion of iPF2 $\alpha$ -III predicts the risk of future thrombotic events. A 10-year follow-up. <i>Thrombosis Research</i> , 2012, 129, 208-211.	0.8	7
106	Aspirin Resistance, Platelet Turnover, and Diabetic Angiopathy: A 2011 Update. <i>Thrombosis Research</i> , 2012, 129, 341-344.	0.8	30
107	TNF- $\alpha$ blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. <i>Internal and Emergency Medicine</i> , 2012, 7, 97-98.	1.0	14
108	Upper tract urothelial cell carcinoma presenting as fever of unknown origin and acid-sterile pyuria. <i>Internal and Emergency Medicine</i> , 2012, 7, 117-118.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 673-680.	1.8	20
110	Efficacy and safety of prophylaxis with once-weekly BAY 794980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. <i>Thrombosis and Haemostasis</i> , 2012, 108, 913-922.	1.8	28
111	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. <i>Haemophilia</i> , 2012, 18, e173-87.	1.0	88
112	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	1.9	129
113	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. <i>Internal and Emergency Medicine</i> , 2012, 7, 9-13.	1.0	32
114	Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. <i>Annals of Medicine</i> , 2011, 43, 531-544.	1.5	37
115	Genotype-independent in vivo oxidative stress following a methionine loading test: Maximal platelet activation in subjects with early-onset thrombosis. <i>Thrombosis Research</i> , 2011, 128, e43-e48.	0.8	14
116	Aspirin resistance and platelet turnover: A 25-year old issue. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 542-545.	1.1	19
117	New Anti-Thrombotic Drugs for Stroke Prevention. <i>Current Vascular Pharmacology</i> , 2011, 9, 723-732.	0.8	9
118	Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 915-919.	1.0	5
119	Alcohol Dosing and the Heart: Updating Clinical Evidence. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 875-884.	1.5	9
120	The Challenge of Diagnosing Pulmonary Embolism in Children, Pregnant Women, and Elderly Patients: A Descriptive Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 908-917.	1.5	4
121	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 267-274.	1.5	44
122	Carotid Intima-Media Thickness in Psoriatic Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 705-712.	1.1	111
123	A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?. <i>Blood Transfusion</i> , 2011, 9 Suppl 2, s14-20.	0.3	3
124	Cost of care of haemophilia with inhibitors. <i>Haemophilia</i> , 2010, 16, e190-201.	1.0	66
125	Homocysteine and arterial thrombosis: Challenge and opportunity. <i>Thrombosis and Haemostasis</i> , 2010, 103, 942-961.	1.8	77
126	Acute coronary syndrome and severe haemophilia: An unusual association with challenging treatment. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1270-1272.	1.8	13



#	ARTICLE	IF	CITATIONS
127	Exploring newer cardioprotective strategies: $\omega$ -3 fatty acids in perspective. <i>Thrombosis and Haemostasis</i> , 2010, 104, 664-680.	1.8	26
128	Mesoglycan: Clinical Evidences for Use in Vascular Diseases. <i>International Journal of Vascular Medicine</i> , 2010, 2010, 1-8.	0.4	23
129	Acquired Haemophilia A in the Elderly: Case Reports. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-5.	1.6	19
130	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. <i>World Journal of Gastroenterology</i> , 2010, 16, 6119.	1.4	57
131	Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 217-223.	1.1	10
132	Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy. <i>Thrombosis Research</i> , 2010, 126, e434-e438.	0.8	14
133	Glanzmann's thrombasthenia (defective platelet integrin $\alpha$ IIb $\beta$ 3): proposals for management between evidence and open issues. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1157-1164.	1.8	57
134	Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 683-694.	1.5	75
135	Diabetes, vascular complications and antiplatelet therapy: open problems. <i>Acta Diabetologica</i> , 2009, 46, 253-261.	1.2	37
136	Perioperative handling of patients on antiplatelet therapy with need for surgery. <i>Internal and Emergency Medicine</i> , 2009, 4, 279-288.	1.0	74
137	Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responder inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1809-1815.	1.9	103
138	Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. <i>Thrombosis Research</i> , 2009, 124, 711-713.	0.8	9
139	Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.. <i>Blood</i> , 2009, 114, 1290-1290.	0.6	0
140	Increased troponin I predicts in-hospital occurrence of hemodynamic instability in patients with sub-massive or non-massive pulmonary embolism independent to clinical, echocardiographic and laboratory information. <i>International Journal of Cardiology</i> , 2008, 124, 351-357.	0.8	37
141	Right-to-left shunt, atrial septal aneurysm and thrombophilia in patients with cryptogenic stroke or TIA vs. those with venous thrombo-embolism. <i>International Journal of Cardiology</i> , 2008, 130, 99-102.	0.8	4
142	Preclinical and prognostically relevant cardiovascular disease burden in systemic lupus erythematosus with low clinical damage index. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, e23-e25.	1.1	2
143	Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: Insights from echocardiography and exercise cardiac performance evaluation. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 262-268.	1.1	43
144	Haemophilia A: molecular insights. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 450-61.	1.4	47

#	ARTICLE	IF	CITATIONS
145	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2250-2257.	1.1	65
146	Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 199-201.	0.5	14
147	Knowledge of cardiovascular risk factors and awareness of non-pharmacological approach for risk prevention in young survivors of acute myocardial infarction. The cardiovascular risk prevention project "Help Your Heart Stay Young". <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 468-472.	1.1	8
148	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2007, 37, 48-53.	1.7	42
149	Glanzmann's Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents. <i>Seminars in Hematology</i> , 2006, 43, S33-S36.	1.8	37
150	Left Ventricular Chamber and Myocardial Systolic Function Reserve in Patients with Type 1 Diabetes Mellitus: Insight from Traditional and Doppler Tissue Imaging Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 848-856.	1.2	20
151	Adverse outcome in women with thrombophilia and bilateral uterine artery notches. <i>Fertility and Sterility</i> , 2006, 86, 726-727.	0.5	5
152	Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus. <i>Thrombosis and Haemostasis</i> , 2006, 95, 1033-1034.	1.8	12
153	A new method for determination of plasma homocystine by isotope dilution and electrospray tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 842, 64-69.	1.2	12
154	Insight into the nature of the CRP's coronary event association using Mendelian randomization. <i>International Journal of Epidemiology</i> , 2006, 35, 922-931.	0.9	159
155	The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1459-1466.	1.9	81
156	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. <i>British Journal of Haematology</i> , 2005, 131, 100-108.	1.2	17
157	EPCR Ser219Gly: Elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. <i>Atherosclerosis</i> , 2005, 183, 283-292.	0.4	56
158	Aspirin resistance and diabetic angiopathy: back to the future. <i>Thrombosis Research</i> , 2004, 113, 97-99.	0.8	18
159	Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 852-857.	1.5	137
160	Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1122-1128.	1.8	42
161	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2322-2329.	1.9	52
162	Denaturing HPLC Procedure for Factor IX Gene Scanning. <i>Clinical Chemistry</i> , 2003, 49, 815-818.	1.5	19

#	ARTICLE	IF	CITATIONS
163	Haemophilia B: From Molecular Diagnosis to Gene Therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 445-51.	1.4	18
164	Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. <i>Journal of Hypertension</i> , 2003, 21, 1415-1423.	0.3	55
165	Polyunsaturated fatty acids, thrombosis and vascular disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 361-364.	0.5	12
166	Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke. <i>Stroke</i> , 2002, 33, 51-56.	1.0	112
167	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 867-873.	1.1	137
168	Preventing adverse obstetric outcomes in women with genetic thrombophilia. <i>Fertility and Sterility</i> , 2002, 78, 371-375.	0.5	90
169	Glanzmann's Thrombasthenia: Identification of 19 New Mutations in 30 Patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1034-1042.	1.8	62
170	Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. <i>Haematologica</i> , 2002, 87, 177-81.	1.7	26
171	Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1034-42.	1.8	14
172	Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. <i>Haematologica</i> , 2002, 87, 1118-9.	1.7	7
173	Severe pancytopenia and intrahepatic cholestasis in a patient with a history of Hodgkin's disease.. <i>European Journal of Internal Medicine</i> , 2001, 12, 515-517.	1.0	0
174	Coexistence of Thrombophilic Gene Polymorphisms Among 559 Unrelated Consecutive Patients With a History of Thrombosis. <i>Thrombosis Research</i> , 2001, 101, 317-319.	0.8	2
175	Fibrinogen Naples I (B <sup>2</sup> A68T) Nonsubstrate Thrombin-Binding Capacities. <i>Thrombosis Research</i> , 2001, 103, 63-73.	0.8	42
176	Plasma Folate, Vitamin B <sub>12</sub> , and Total Homocysteine and Homozygosity for the C677T Mutation of the 5,10-Methylene Tetrahydrofolate Reductase Gene in Patients with Alzheimer's Dementia. <i>Gerontology</i> , 2001, 47, 324-329.	1.4	81
177	Inherited Thrombophilic Risk Factors and Venous Thromboembolism. <i>Chest</i> , 2000, 118, 1405-1411.	0.4	79
178	Homocysteine, Coagulation, Platelet Function, and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 243-254.	1.5	131
179	C-Reactive Protein in Offspring Is Associated With the Occurrence of Myocardial Infarction in First-Degree Relatives. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 198-203.	1.1	49
180	Idiopathic Budd-Chiari syndrome in a patient with homozygous Factor V Leiden and heterozygous Factor II G20210A mutations. <i>Thrombosis Research</i> , 2000, 100, 567-568.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Persistent Impairment of Platelet Aggregation following Cessation of a Short-course Dietary Supplementation of Moderate Amounts of N-3 Fatty Acid Ethyl Esters. <i>Thrombosis and Haemostasis</i> , 1999, 82, 128-133.	1.8	26
182	Inherited Prothrombotic Conditions and Premature Ischemic Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1751-1756.	1.1	113
183	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1368-1377.	1.1	287
184	Anticardiolipin Antibodies in Patients With Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 2983-2987.	0.2	78
185	Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. <i>American Journal of Cardiology</i> , 1999, 83, 1196-1200.	0.7	38
186	The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commercial Confirmatory System Tests. <i>Thrombosis Research</i> , 1999, 94, 373-380.	0.8	6
187	Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 179, 1324-1328.	0.7	168
188	Identifying human platelet glycoproteins IIb and IIIa by capillary electrophoresis. <i>Electrophoresis</i> , 1998, 19, 1468-1474.	1.3	5
189	PAI-1 Plasma Levels in a General Population Without Clinical Evidence of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 562-567.	1.1	140
190	A Fast and Accurate Method for Genotyping the Angiotensin-Converting Enzyme I/D Polymorphism. <i>Circulation</i> , 1998, 97, 1213-1214.	1.6	10
191	Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke. <i>Stroke</i> , 1998, 29, 399-403.	1.0	80
192	Homozygous C677T Mutation of the 5,10 Methylenetetrahydrofolate Reductase Gene and Hyperhomocysteinemia in Italian Patients With a History of Early-Onset Ischemic Stroke. <i>Stroke</i> , 1998, 29, 869-871.	1.0	40
193	The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 152-156.	1.1	128
194	Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. <i>Journal of Hypertension</i> , 1998, 16, 985-991.	0.3	11
195	Endothelin Abnormalities in Patients With Pulmonary Embolism. <i>Chest</i> , 1997, 111, 544-549.	0.4	37
196	Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiotensin Converting Enzyme (ACE) Genes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2082-2087.	1.1	69
197	High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. <i>Diabetologia</i> , 1997, 40, 1191-1196.	2.9	69
198	Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?. <i>Cardiovascular Drugs and Therapy</i> , 1997, 10, 743-749.	1.3	2

#	ARTICLE	IF	CITATIONS
199	Deletion Polymorphism in the Angiotensin-Converting Enzyme Gene in Patients With a History of Ischemic Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 304-309.	1.1	68
200	Fibrinolytic, platelet and monocyte variables in homozygous familial hypercholesterolemia. The effect of a regular plasma cholesterol removal by LDL-apheresis. <i>Fibrinolysis</i> , 1993, 7, 63-64.	0.5	6
201	Drugs affecting plasma fibrinogen levels. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 25-27.	1.3	24
202	Searching for the thrombogenic mechanism(s) of fibrinogen. <i>Thrombosis Research</i> , 1990, 57, 61-67.	0.8	5
203	Newer agents for coronary thrombolysis. Perspectives from clinical studies. <i>Pharmacological Research</i> , 1989, 21, 153-161.	3.1	7
204	Aspirin as an antithrombotic agent. , 1989, 33, 43-62.		0
205	The Causal Role of Salt Depletion in Acute Renal Failure Due to Captopril in Hypertensive Patients with a Single Functioning Kidney and Renal Artery Stenosis. <i>Renal Failure</i> , 1987, 10, 9-20.	0.8	20
206	Effects of PGE <sub>2</sub> Infusion on Renal Function in Normal Man before and after Angiotensin II Inhibition by Captopril. <i>Kidney and Blood Pressure Research</i> , 1987, 10, 289-296.	0.9	0
207	Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. <i>American Journal of Medicine</i> , 1985, 79, 552-559.	0.6	228
208	Arachidonic acid induces human platelet-fibrin retraction: The role of platelet cyclic endoperoxides. <i>Thrombosis Research</i> , 1982, 25, 299-306.	0.8	3
209	Increased PGI <sub>2</sub> activity in venous tissues from rats on oral contraceptives is not prevented by heparin administration before vessel isolation. <i>Thrombosis Research</i> , 1980, 18, 895-896.	0.8	3
210	Plasmatic and vascular factors of the hemostatic system in rats receiving an estrogen-progestogen combination. <i>Contraception</i> , 1980, 22, 249-257.	0.8	2
211	Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an destrogen-progestagen combination. <i>Thrombosis Research</i> , 1979, 14, 793-797.	0.8	34
212	DIPYRIDAMOLE AND PLATELET FUNCTION. <i>Lancet, The</i> , 1978, 312, 1257-1259.	6.3	14